

Case Number:	CM14-0028229		
Date Assigned:	06/13/2014	Date of Injury:	06/12/2005
Decision Date:	07/16/2014	UR Denial Date:	01/31/2014
Priority:	Standard	Application Received:	03/05/2014

HOW THE IMR FINAL DETERMINATION WAS MADE

MAXIMUS Federal Services sent the complete case file to an expert reviewer. He/she has no affiliation with the employer, employee, providers or the claims administrator. The expert reviewer is Board Certified in Anesthesiology has a subspecialty in Pain Management and is licensed to practice in California. He/she has been in active clinical practice for more than five years and is currently working at least 24 hours a week in active practice. The expert reviewer was selected based on his/her clinical experience, education, background, and expertise in the same or similar specialties that evaluate and/or treat the medical condition and disputed items/services. He/she is familiar with governing laws and regulations, including the strength of evidence hierarchy that applies to Independent Medical Review determinations.

CLINICAL CASE SUMMARY

The expert reviewer developed the following clinical case summary based on a review of the case file, including all medical records:

According to the records made available for review, this is a 44-year-old female with a 6/12/05 date of injury. At the time (1/23/14) of the request for authorization for compound #60 ingredient(s): flurbiprofen powder, cyclobenzaprine powder, gabapentin powder, lidocaine powder, prilocaine powder, PCCA CRE LIP-Max, there is documentation of subjective (right elbow pain) and objective (slight tenderness to palpation over the medial epicondyle and to a greater degree at the lateral epicondyle with resist to her flexion and extension) findings, current diagnoses (bilateral lateral epicondylitis right improved and left medial epicondylitis), and treatment to date (heat and paraffin wax).

IMR ISSUES, DECISIONS AND RATIONALES

The Final Determination was based on decisions for the disputed items/services set forth below:

**COMPOUND #60 INGREDIENT(S): FLURBIPROFEN POWDER ,
CYCLOBENZAPRINE POWDER, GABAPENTIN POWDER, LIDOCAINE POWDER,
PRILOCAINE POWDER, PCCA CRE LIP-MAX: Upheld**

Claims Administrator guideline: Decision based on MTUS Chronic Pain Treatment Guidelines : CHRONIC PAIN MEDICAL TREATMENT GUIDELINES, TOPICAL ANALGESICS.

MAXIMUS guideline: Decision based on MTUS Chronic Pain Treatment Guidelines Topical Analgesics Page(s): 111-113.

Decision rationale: MTUS Chronic Pain Medical Treatment Guidelines identifies that many agents are compounded as monotherapy or in combination for pain control; that ketoprofen, lidocaine (in creams, lotion or gels), capsaicin in a 0.0375% formulation, baclofen and other muscle relaxants, and gabapentin and other antiepilepsy drugs are not recommended for topical applications; and that any compounded product that contains at least one drug (or drug class) that is not recommended, is not recommended. Within the medical information available for review, there is documentation of diagnoses of bilateral lateral epicondylitis right improved and left medial epicondylitis. However, compound #60 ingredient(s): flurbiprofen powder, cyclobenzaprine powder, gabapentin powder, lidocaine powder, prilocaine powder, PCCA CRE LIP-Max contains drugs (or drug classes) (cyclobenzaprine (muscle relaxant), gabapentin, and lidocaine) that are not recommended. Therefore, based on guidelines and a review of the evidence, the request for compound #60 ingredient(s): flurbiprofen powder, cyclobenzaprine powder, gabapentin powder, lidocaine powder, prilocaine powder, PCCA CRE LIP-Max is not medically necessary.